Corticosteroids Market Report 2025

This Corticosteroids market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The corticosteroids market size has grown steadily in recent years. It will grow from $5.47 billion in 2024 to $5.7 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to treatment of inflammatory conditions, autoimmune disorders and immune system suppression, respiratory conditions and asthma management, allergic reactions and dermatological applications, cancer treatment support.

The corticosteroids market size is expected to see strong growth in the next few years. It will grow to $7.24 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising incidence of chronic diseases, expanding applications in rheumatology, advancements in drug delivery, geriatric population growth, research and development in corticosteroid therapeutics. Major trends in the forecast period include immunomodulatory effects emphasis, biosimilar market growth, combination therapies development, pediatric-specific formulations, regulatory compliance focus.

The growing demand for cancer treatment is expected to drive the expansion of the corticosteroid market in the coming years. Cancer treatment includes various therapies - such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted treatments - aimed at eliminating cancer cells and alleviating symptoms. Several factors contribute to the increasing demand for cancer treatment, including the rising incidence of cancer, enhanced awareness and screening efforts, better access to healthcare, and the availability of supportive care services. Corticosteroids help alleviate symptoms and improve the tolerability of cancer treatments, which leads to better patient outcomes and further supports the demand for comprehensive cancer care. For example, in May 2024, the National Health Service (NHS) in the UK reported that treatment activity reached an all-time high, with over 1,400 patients beginning cancer treatment each working day. From April 2023 to March 2024, nearly 340,000 individuals received their first cancer treatment. Consequently, the increasing demand for cancer treatment is propelling the growth of the corticosteroid market.

The rising prevalence of respiratory diseases is anticipated to drive the growth of the corticosteroids market in the future. Corticosteroids are commonly prescribed for conditions such as rhinitis, pneumonitis, sarcoidosis, asthma exacerbations, COPD exacerbations, anaphylaxis, urticaria, and angioedema. Many respiratory ailments, including asthma and COPD exacerbations, anaphylaxis, urticaria and angioedema, rhinitis, pneumonitis, sarcoidosis, and interstitial lung disease, are treated with corticosteroids. For example, in May 2024, Asthma Australia, a national not-for-profit organization, reported that asthma mortality rates in Australia rose from 349 deaths in 2021 to 455 deaths in 2022, highlighting a concerning trend regarding this chronic respiratory condition. As a result, the increasing incidence of respiratory diseases is propelling the corticosteroids market forward.

An emerging trend in the corticosteroid therapy market is the development of silicones for topical and transdermal drug delivery. Silicone gel sheets and implants are being used to deliver drugs effectively, and silicone-based pressure-sensitive adhesives for transdermal drug delivery show promising results. Silicones offer advantages such as improved drug permeability and high diffusivity, making them efficient for modern drug products.

Major companies in the corticosteroid market are focusing on innovation to expand their customer bases and increase revenue. The development of rescue medications, such as AstraZeneca's Airsupra, indicates a commitment to meeting immediate relief needs for acute symptoms. AstraZeneca's product, a fixed-dose combination rescue medication, received FDA approval in January 2023, containing albuterol and budesonide for bronchoconstriction treatment and asthma exacerbation prevention.

In June 2024, Sun Pharmaceutical Industries Ltd., a specialty generic pharmaceutical company based in India, acquired Taro Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition aims to enhance Sun Pharma's position in the pharmaceutical market, particularly in the sectors of off-patent pharmaceuticals, prescription medications, and over-the-counter products. Taro Pharmaceutical Industries Ltd., located in Israel, is a research-focused pharmaceutical manufacturer that produces a range of products, including corticosteroids.

Corticosteroid therapy involves administering treatment in various forms to suppress the immune system and alleviate inflammation. It is employed in addressing conditions such as asthma, hay fever, and urticaria (hives) associated with allergy symptoms. Corticosteroids, also referred to as steroids, represent a category of anti-inflammatory medications.

The primary classifications of corticosteroid therapy include glucocorticoids and mineralocorticoids. Glucocorticoids, a specific type of corticosteroid hormone, are highly effective in immune system suppression and inflammation reduction. This therapeutic approach finds application in treating skin allergies, rheumatology indications, endocrinology, and acute respiratory diseases in medical facilities, clinics, research institutes, and other healthcare settings.

The corticosteroids therapy market research report is one of a series of new reports that provides corticosteroids therapy market statistics, including corticosteroids therapy industry global market size, regional shares, competitors with a corticosteroids therapy market share, detailed corticosteroids therapy market segments, market trends and opportunities, and any further data you may need to thrive in the corticosteroids therapy industry. This corticosteroid therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the corticosteroids market include McKesson Corporation, Pfizer Inc., Johnson and Johnson Services Inc., Merck & Co.Inc., Bayer AG, Sumitomo Corporation, Novartis International AG., Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals Ltd., LEO Pharma A/S, Glenmark Pharmaceuticals Ltd., Wockhardt Limited, Indivior plc, Zizhu Pharmaceutical Co. Ltd., Allergan plc, Hikma Pharmaceuticals plc.

North America was the largest region in the corticosteroids therapy market share in 2024. Middle East is expected to be the largest growing region in the global corticosteroids market during the forecast period. The regions covered in the corticosteroids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corticosteroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The corticosteroids therapy market consists of sales of glucocorticoids, mineralocorticoids, cortisone, hydrocortisone, and prednisone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.